NO20031852L - Pyrimidin-2,4,6-trion metalloproteinase inhibitorer - Google Patents

Pyrimidin-2,4,6-trion metalloproteinase inhibitorer

Info

Publication number: NO20031852L
Authority: NO; Norway
Prior art keywords: pyrimidine; metalloproteinase inhibitors; trione metalloproteinase; trione; inhibitors
Prior art date: 2000-10-26

Application number

NO20031852A

Other languages

English (en)

Other versions

NO20031852D0 (no

Inventor

Marc Carl Noe

Lawrence Alan Reiter

Martin James Wythes

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-26

Filing date

2003-04-24

Publication date

2003-06-23

2003-04-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-04-24 Publication of NO20031852D0 publication Critical patent/NO20031852D0/no

2003-06-23 Publication of NO20031852L publication Critical patent/NO20031852L/no

Links

HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 title 1
239000003475 metalloproteinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Dental Preparations (AREA)
Plural Heterocyclic Compounds (AREA)

NO20031852A 2000-10-26 2003-04-24 Pyrimidin-2,4,6-trion metalloproteinase inhibitorer NO20031852L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24331400P	2000-10-26	2000-10-26
PCT/IB2001/001953 WO2002034726A2 (en)	2000-10-26	2001-10-17	Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (2)

Publication Number	Publication Date
NO20031852D0 NO20031852D0 (no)	2003-04-24
NO20031852L true NO20031852L (no)	2003-06-23

Family

ID=36950891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031852A NO20031852L (no)	2000-10-26	2003-04-24	Pyrimidin-2,4,6-trion metalloproteinase inhibitorer

Country Status (36)

Country	Link
US (2)	US6706723B2 (no)
EP (1)	EP1332136A2 (no)
JP (1)	JP2004512327A (no)
KR (1)	KR20030061825A (no)
CN (1)	CN1714084A (no)
AP (1)	AP2001002319A0 (no)
AR (1)	AR035362A1 (no)
AU (1)	AU2002210800A1 (no)
BG (1)	BG107651A (no)
BR (1)	BR0114917A (no)
CA (1)	CA2425280A1 (no)
CR (1)	CR6939A (no)
CZ (1)	CZ20031069A3 (no)
EA (1)	EA200300409A1 (no)
EC (1)	ECSP034568A (no)
EE (1)	EE200300195A (no)
GT (1)	GT200100214A (no)
HN (1)	HN2001000243A (no)
HR (1)	HRP20030331A2 (no)
HU (1)	HUP0302337A3 (no)
IL (1)	IL154946A0 (no)
IS (1)	IS6749A (no)
MA (1)	MA26956A1 (no)
MX (1)	MXPA03003734A (no)
NO (1)	NO20031852L (no)
NZ (1)	NZ524774A (no)
OA (1)	OA12528A (no)
PA (1)	PA8531501A1 (no)
PE (1)	PE20020585A1 (no)
PL (1)	PL362919A1 (no)
SK (1)	SK4872003A3 (no)
SV (1)	SV2003000704A (no)
TN (1)	TNSN01150A1 (no)
UY (1)	UY26981A1 (no)
WO (1)	WO2002034726A2 (no)
ZA (1)	ZA200302192B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0109991A (pt) *	2000-04-11	2003-05-27	Sankyo Co	Composição farmacêutica
AP2001002319A0 (en) *	2000-10-26	2001-12-31	Pfizer Prod Inc	Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
MXPA03005870A (es)	2001-02-14	2005-02-14	Warner Lambert Co	Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
JP2004518723A (ja)	2001-02-14	2004-06-24	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	ピリミジンマトリックスメタロプロテイナーゼ阻害剤
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
MXPA04002537A (es)	2001-10-12	2004-05-31	Warner Lambert Co	Alquinos como inhibidores de metaloproteinasa de matriz.
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
AU2002346729A1 (en)	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US7294624B2 (en) *	2001-12-20	2007-11-13	Bristol Myers Squibb Company	Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
NI200300045A (es) *	2002-04-26	2005-07-08	Pfizer Prod Inc	Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
AU2003216660A1 (en) *	2002-04-26	2003-11-10	Pfizer Products Inc.	N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
JP2005527598A (ja)	2002-04-26	2005-09-15	ファイザー・プロダクツ・インク	トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
MXPA04010550A (es) *	2002-04-26	2005-01-25	Pfizer Prod Inc	Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona.
AU2003250470A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
MXPA05001603A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
AU2003249477A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Heterobicylcic metalloproteinase inhibitors
WO2004014375A2 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
MXPA05001786A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
WO2004014378A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003253186A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
MXPA05001783A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
CA2497658A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Chromone derivatives as matrix metalloproteinase inhibitors
GB0223249D0 (en) *	2002-10-08	2002-11-13	Amersham Plc	Improved imaging agents
WO2004084903A1 (en) *	2003-03-27	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) *	2003-03-28	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment of chronic wounds
WO2004089294A2 (en)	2003-04-04	2004-10-21	Incyte Corporation	Compositions, methods and kits relating to her-2 cleavage
WO2005097133A1 (en) *	2004-04-01	2005-10-20	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
WO2005118166A2 (en)	2004-06-04	2005-12-15	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical composition containing irbesartan
TW200806648A (en) *	2005-11-29	2008-02-01	Sankyo Co	Acid addition salts of dihydropyridine derivatives
TW200736245A (en) *	2005-11-29	2007-10-01	Sankyo Co	Acid addition salts of optically active dihydropyridine derivatives
WO2010129665A2 (en)	2009-05-05	2010-11-11	Cambria Pharmaceuticals, Inc.	Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
RU2400233C1 (ru)	2009-07-07	2010-09-27	Общество с ограниченной ответственностью "Вирфарм"	Способ лечения заболеваний печени различного генеза
KR101301533B1 (ko) *	2010-02-09	2013-09-04	한미사이언스 주식회사	암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
AP3339A (en)	2011-03-14	2015-07-31	Boehringer Ingelheim Int	Benzodioxane inhibitors of leukotriene production
US9139567B2 (en)	2011-07-19	2015-09-22	Boehringer Ingelheim International Gmbh	Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
AR091315A1 (es)	2012-03-06	2015-01-28	Boehringer Ingelheim Int	Inhibidores de benzodioxano de la produccion de leucotrieno
JP6080226B2 (ja)	2012-03-06	2017-02-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
WO2014014874A1 (en)	2012-07-17	2014-01-23	Boehringer Ingelheim International Gmbh	Pyrazole derivatives which inhibit leukotriene production
WO2014042647A1 (en) *	2012-09-14	2014-03-20	Levina Elizabeth	Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
WO2015009609A1 (en)	2013-07-15	2015-01-22	Boehringer Ingelheim International Gmbh	Inhibitors of leukotriene production
JP2016523982A (ja)	2013-07-15	2016-08-12	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ロイコトリエン生成の阻害剤
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
IL315313A (en) *	2018-08-24	2024-10-01	Xeniopro GmbH	Aromatic molecules for use in the treatment of pathological conditions
CA3221177A1 (en)	2021-11-01	2023-05-04	Meghan Kerrisk Campbell	Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
CN119614460B (zh) *	2025-02-11	2025-04-18	云南农业大学	一种降解丁布的变栖克雷伯氏菌bs2309菌株及其应用
CN119970733B (zh) *	2025-02-28	2026-06-19	南京医科大学	一种新化合物在制备预防与治疗缺血性脑卒中药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19548624A1 (de)	1995-12-23	1997-06-26	Boehringer Mannheim Gmbh	Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0989982B1 (en) *	1997-06-21	2005-08-17	Roche Diagnostics GmbH	Barbituric acid derivatives with antimetastatic and antitumor activity
DE19726427A1 (de)	1997-06-23	1998-12-24	Boehringer Mannheim Gmbh	Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6265578B1 (en)	1999-02-12	2001-07-24	Hoffmann-La Roche Inc.	Pyrimidine-2,4,6-triones
HN2000000137A (es) *	1999-08-12	2001-02-02	Pfizer Prod Inc	Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
AP2001002319A0 (en) *	2000-10-26	2001-12-31	Pfizer Prod Inc	Pyrimidine-2,4,6-trione metalloproteinase inhibitors.

2001
- 2001-10-17 AP APAP/P/2001/002319A patent/AP2001002319A0/en unknown
- 2001-10-17 CA CA002425280A patent/CA2425280A1/en not_active Abandoned
- 2001-10-17 BR BR0114917-2A patent/BR0114917A/pt not_active IP Right Cessation
- 2001-10-17 WO PCT/IB2001/001953 patent/WO2002034726A2/en not_active Ceased
- 2001-10-17 JP JP2002537717A patent/JP2004512327A/ja not_active Withdrawn
- 2001-10-17 MX MXPA03003734A patent/MXPA03003734A/es unknown
- 2001-10-17 AU AU2002210800A patent/AU2002210800A1/en not_active Abandoned
- 2001-10-17 IL IL15494601A patent/IL154946A0/xx unknown
- 2001-10-17 EP EP01978707A patent/EP1332136A2/en not_active Withdrawn
- 2001-10-17 SK SK487-2003A patent/SK4872003A3/sk unknown
- 2001-10-17 HR HR20030331A patent/HRP20030331A2/hr not_active Application Discontinuation
- 2001-10-17 KR KR10-2003-7005756A patent/KR20030061825A/ko not_active Ceased
- 2001-10-17 PL PL01362919A patent/PL362919A1/xx not_active Application Discontinuation
- 2001-10-17 HU HU0302337A patent/HUP0302337A3/hu unknown
- 2001-10-17 EE EEP200300195A patent/EE200300195A/xx unknown
- 2001-10-17 CN CNA018180841A patent/CN1714084A/zh active Pending
- 2001-10-17 OA OA1200300122A patent/OA12528A/en unknown
- 2001-10-17 NZ NZ524774A patent/NZ524774A/en unknown
- 2001-10-17 EA EA200300409A patent/EA200300409A1/ru unknown
- 2001-10-17 CZ CZ20031069A patent/CZ20031069A3/cs unknown
- 2001-10-23 UY UY26981A patent/UY26981A1/es not_active Application Discontinuation
- 2001-10-24 AR ARP010104976A patent/AR035362A1/es unknown
- 2001-10-24 PE PE2001001051A patent/PE20020585A1/es not_active Application Discontinuation
- 2001-10-24 HN HN2001000243A patent/HN2001000243A/es unknown
- 2001-10-25 TN TNTNSN01150A patent/TNSN01150A1/fr unknown
- 2001-10-25 GT GT200100214A patent/GT200100214A/es unknown
- 2001-10-25 US US10/032,837 patent/US6706723B2/en not_active Expired - Fee Related
- 2001-10-25 SV SV2001000704A patent/SV2003000704A/es unknown
- 2001-10-26 PA PA20018531501A patent/PA8531501A1/es unknown
2003
- 2003-03-17 IS IS6749A patent/IS6749A/is unknown
- 2003-03-19 ZA ZA200302192A patent/ZA200302192B/en unknown
- 2003-03-20 BG BG107651A patent/BG107651A/bg unknown
- 2003-03-26 CR CR6939A patent/CR6939A/es not_active Application Discontinuation
- 2003-04-21 MA MA27114A patent/MA26956A1/fr unknown
- 2003-04-24 NO NO20031852A patent/NO20031852L/no not_active Application Discontinuation
- 2003-04-25 EC EC2003004568A patent/ECSP034568A/es unknown
2004
- 2004-02-13 US US10/778,990 patent/US20050107414A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20031852D0 (no)	2003-04-24
WO2002034726A3 (en)	2002-10-17
AR035362A1 (es)	2004-05-12
AU2002210800A1 (en)	2002-05-06
PA8531501A1 (es)	2003-06-30
CN1714084A (zh)	2005-12-28
AP2001002319A0 (en)	2001-12-31
NZ524774A (en)	2004-09-24
PE20020585A1 (es)	2002-07-06
KR20030061825A (ko)	2003-07-22
WO2002034726A9 (en)	2003-03-06
PL362919A1 (en)	2004-11-02
US6706723B2 (en)	2004-03-16
HRP20030331A2 (en)	2003-06-30
BG107651A (bg)	2003-12-31
EP1332136A2 (en)	2003-08-06
ECSP034568A (es)	2003-06-25
HUP0302337A3 (en)	2004-01-28
MA26956A1 (fr)	2004-12-20
SV2003000704A (es)	2003-01-13
TNSN01150A1 (fr)	2005-11-10
HN2001000243A (es)	2002-11-07
CA2425280A1 (en)	2002-05-02
IL154946A0 (en)	2003-10-31
US20020132822A1 (en)	2002-09-19
ZA200302192B (en)	2004-05-05
HUP0302337A2 (hu)	2003-10-28
CR6939A (es)	2003-11-25
SK4872003A3 (en)	2004-08-03
IS6749A (is)	2003-03-17
EA200300409A1 (ru)	2003-08-28
CZ20031069A3 (cs)	2004-05-12
WO2002034726A2 (en)	2002-05-02
UY26981A1 (es)	2002-06-20
JP2004512327A (ja)	2004-04-22
MXPA03003734A (es)	2003-07-28
BR0114917A (pt)	2003-07-01
OA12528A (en)	2006-06-02
US20050107414A1 (en)	2005-05-19
EE200300195A (et)	2003-10-15
GT200100214A (es)	2002-07-03

Legal Events

Date	Code	Title	Description
2006-05-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20031852D0 (no)	2003-04-24	Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO20020662D0 (no)	2002-02-11	Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO20031853L (no)	2003-06-23	Spiro-pyrimidin-2,4,6-trion metalloproteinaseinhibitorer
DK1303496T3 (da)	2007-12-27	Pyrimidinderivater
MA26881A1 (fr)	2004-12-20	5-alkyl-pyrido [2,3-d]pyrimidines inhibitrices de tyrosine-kinases.
CY2015035I2 (el)	2016-04-13	Ενωσεις πυριμιδινης
NO20024127D0 (no)	2002-08-29	Pyrimidin-forbindelser
HUS1500055I1 (hu)	2016-03-29	HIV-gátló pirimidinszármazékok
AU2003219410A8 (en)	2003-11-10	Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
ATE455107T1 (de)	2010-01-15	Hiv-replikationshemmende pyrimidine
NO20031238D0 (no)	2003-03-18	Xantin-fosfodiesterase V-inhibitorer
NO20042742L (no)	2004-08-24	Pyrimidinforbindelser
NO20032291D0 (no)	2003-05-21	Pyrimidinderivater
ATE277912T1 (de)	2004-10-15	Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer
ATE276260T1 (de)	2004-10-15	2-aminoalkyl-thieno(2,3-d)pyrimidine
DK1153015T3 (da)	2005-02-07	Pyrimidin-2,4,6-trioner som inhibitorer af matrix-metalloproteinaser